I am really hoping that IPD survives. IPD does not need money at...

I am really hoping that IPD survives.
IPD does not need money at all, has right excellent evolving board and management now - to really grow & transcend now.
The company has attained not only commercialisation success in recent many years and reimbursement medical codes achievement and being global standard of care for indication, but also now bridging to cashflow positive & then onwards to being very successful.
Now written into guidelines of cancer treatment and care since March last year, is effectively the required standard duty of care, now into the NCCN survivorship cancer treatment guidelines.

A big long road to fully develop, wheras the companies you mention as well as here - yes likely get taken over , by a major before same stage.

It was incredible , but through time now, now longterm large shareholders voted resoundingly to bring in an upgraded transcendent board and management,.. specifically because now after all the years supported, they do not want a nearterm takeover as so often occurs now.
But still high risk a low ball takeout.

It has been a long journey, so much that shareholders have gone through- but the company has actually made it and can and will manifest on its path. I hope so very much anyway.
But as you expressed, a takeover before full value realisation is usually more likely,

Bringing up also- as not been discussed , and only issue had previously also been the former chairman & imo his limitations.
However ‘nice ‘ someone can be , but also he exerted power over the board and who selected in it, & with his views for everyone leading, including a chum Ceo— even though he was not an executive chair.
Not committed enough imo, similar complaints to here with former, and also involved with multiple other companies . As was the last CEO.
And at junctures was not fast enough to recognise need for some pivotal actions 5 years ago, delays in foreseeing need for additional trial as then occurred, and too much oversight by him from when he got elected to the role pre Covid he lead as if he was. (Acted esp recent years, at helm of success evolving, but as if he was like an ‘Executive chairman’)

This is the style, frequently , of US listed biotech and companies, the large majority that do not make money significantly, though also raise a lot of money.
Shareholders becoming diluted with typically each large raise. Can think of a particular asx listed biotech also given their shareholders similar trajectory recent years.

DS from formerly here, nice man & a supporter and keen to serve the company, but a funds- raising guy who previously had been involved in a number of cap raises for IPD with cannacorde., was recruited by him , and truly was not required.

Finance people are not needed, good scientists, and IP specialists perhaps and past successful drug & tech global developers, people who really roll up their sleeves and work to progress the company, are who small biotech companies need on board.
I note that the former chairman here also was at helm when DS was recruited here- and arguably was also not in shareholders main interests, to have a purely financial guy aboard the board.